Literature DB >> 25956526

Revision of Articular Surface Replacement (ASR) Total Hip Arthroplasty: Correlation of Perioperative Data and Early Post-Revision Outcome Results.

Johannes Cip1, Christian Bach1, Mark Widemschek1, Matthias Luegmair1, Arno Martin1.   

Abstract

The articular surface replacement (ASR) total hip arthroplasty (THA) showed accelerated failure rates due to adverse-reaction to metal debris (ARMD). Literature correlating preoperative with intraoperative revision findings respectively post-revision outcome results are rare. 30 of 99 available ASR THA were revised due to ARMD. Mean post-revision follow-up term was 2.3 years. In part, preoperative data did not correlate with intraoperative revision findings. ARMD was even found in asymptomatic patients with non-elevated ion levels. Postoperative pain and metal ions decreased significantly (P ≤ 0.016). Cobalt decreased faster than chrome. Patients with intraoperative pseudotumors, osteolysis or bilateral THA did not have higher pre- or postoperative ion values (P ≥ 0.053). Females showed higher postoperative chrome levels (P=0.031). One major post-revision complication (femoral nerve palsy) and one re-revision (late onset infection) occurred.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASR; articular surface replacement; outcome; revision; total hip arthroplasty

Mesh:

Substances:

Year:  2015        PMID: 25956526     DOI: 10.1016/j.arth.2015.04.010

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  CORR Insights®: What Is the Long-term Survival for Primary THA With Small-head Metal-on-metal Bearings?

Authors:  Alexander Jaime Grübl
Journal:  Clin Orthop Relat Res       Date:  2018-06       Impact factor: 4.176

2.  Revision surgery of metal-on-metal hip arthroplasties for adverse reactions to metal debris.

Authors:  Gulraj S Matharu; Antti Eskelinen; Andrew Judge; Hemant G Pandit; David W Murray
Journal:  Acta Orthop       Date:  2018-03-01       Impact factor: 3.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.